Non-Alcoholic Fatty Liver Disease (NAFLD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition where excess fat accumulates in the liver of individuals who consume minimal or no alcohol. The most common type of NAFLD is referred to as fatty liver, which is generally not considered a serious ailment. In fatty liver, fat accumulates within the liver cells. A smaller subset of people with NAFLD may experience a more severe condition known as non-alcoholic steatohepatitis (NASH). NASH is characterized by fat accumulation accompanied by inflammation of liver cells and varying degrees of scarring. This condition poses a potential threat as it can progress to severe liver scarring and cirrhosis. Cirrhosis occurs when the liver undergoes significant damage, gradually replaced by scar tissue, impairing its proper functioning. Most individuals with NAFLD do not exhibit symptoms and pass a normal physical examination. Symptoms like abdominal pain (typically in the center or upper right abdomen) and occasional fatigue may be observed in children. However, it is essential to consider other potential causes of abdominal pain and fatigue. During a physical examination, the liver may be slightly enlarged, and some children may display patchy, dark skin discoloration, most commonly seen in the neck and underarm area, known as acanthosis nigricans. NAFLD is part of the metabolic syndrome, which includes diabetes or pre-diabetes (insulin resistance), being overweight or obese, elevated blood lipids such as cholesterol and triglycerides, and high blood pressure. It's important to note that not all patients exhibit all aspects of the metabolic syndrome. The exact causes of NASH development are not fully understood, but several factors may contribute to its onset. These factors encompass oxidative stress (an imbalance between pro-oxidant and antioxidant chemicals leading to liver cell damage), the production and release of inflammatory proteins (cytokines) by the patient's inflammatory cells, liver cells, or fat cells, liver cell necrosis or apoptosis, inflammation, and infiltration of adipose tissue (fat tissue) by white blood cells, and the potential role of gut microbiota (intestinal bacteria) in liver inflammation. NAFLD can lead to liver inflammation, resulting in liver swelling (steatohepatitis), which may progress to scarring (cirrhosis) over time and, in severe cases, lead to liver cancer or liver failure. NAFLD progresses through four primary stages, with most individuals remaining in the initial stage without realizing it. In a small percentage of cases, it may advance and potentially lead to liver damage if left undetected and untreated. The primary stages of NAFLD include:

1.       Simple fatty liver (steatosis): This stage involves a mostly harmless fat accumulation within the liver cells, often detected incidentally during other medical tests.

2.       Non-alcoholic steatohepatitis (NASH): NASH represents a more severe form of NAFLD characterized by liver inflammation, affecting an estimated 5% of the UK population.

3.       Fibrosis: Persistent inflammation leads to the formation of scar tissue around the liver and nearby blood vessels, but the liver can still function normally at this stage.

4.       Cirrhosis: This is the most advanced stage, after years of inflammation, resulting in liver shrinkage, scarring, and a lumpy appearance. Cirrhosis leads to permanent liver damage, resulting in liver failure and liver cancer.

Initial suspicion of non-alcoholic fatty liver disease arises when blood tests show elevated liver enzyme levels. However, additional tests are conducted to rule out other liver diseases. An ultrasound is often employed to confirm the diagnosis of NAFLD. Currently, there is no specific medication available for the treatment of NAFLD.

·       It is estimated that approximately 25% of adults in the United States have NAFLD, with about 20% of those individuals having NASH (equivalent to 5% of all adults in the U.S.).

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Non-Alcoholic Fatty Liver Disease (NAFLD) – market outlook, epidemiology, competitive landscape, and market forecast report – 2022 to 2032